Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Related REGN
Market Wrap For April 16: Markets Hold On To Gains On Positive Yellen Comments And Economic Data
UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals on Expected Continued Pipeline Success
Related SNY
Impax to Sell Authorized Generic Renvela - Analyst Blog
Prestige Brands Gains on Product Acquisition News - Analyst Blog
Novo Nordisk Upgraded to 'Buy' (Fox Business)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Most Popular

Related Articles (REGN + SNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free